How strong are your clinical trial transparency policies? New checklist

22 Aug 2018

TranspariMED has developed a simple checklist to enable research funders, universities and other clinical trial sponsors to assess their current policies against WHO best practices, identify gaps, and pinpoint areas that require strengthening. 

 

Based on an audit tool originally compiled by the team at EBM Data Lab, the checklist is based on the WHO Joint Statement on public disclosure of results from clinical trials, which has so far been signed by six of the largest non-commercial medical research funders worldwide.

 

Click on the image below to download this simple one-page tool as a PDF.

 

 

Out of the world's 19 largest non-commercial medical research funders, six have already signed up to the WHO Joint Statement:

 

  • Bill and Melinda Gates Foundation (US)

  • Horizon 2020 (European Commission)

  • Inserm (France)

  • Medical Research Council (UK)

  • National Institute for Health Research (UK)

  • Wellcome Trust (UK)

 

(Note that some signatories’ performance on delivering on their promises has been mixed.)

 

The remaining 13 top funders have yet to sign up:

 

  • Australian National Health and Medical Research Council (NHMRC)

  • Canadian Institutes of Health Research

  • Centre National de la Recherche Scientifique (CNRS, France)

  • Federal Ministry of Education and Research of Germany (BMBF)

  • German Research Foundation (DFG)

  • Instituto de Salud Carlos III

  • Japan Science and Technology Agency

  • Japan Society for Promotion of Science

  • Ministry of Health of China

  • Ministry of Health of Italy

  • National Institutes of Health (NIH, United States)

  • National Natural Science Foundation of China (NSFC)

  • US Department of Defence (CDMRP, United States)

 

To date, not a single university has signed up to the WHO Joint Statement. 

 

TranspariMED encourages all non-commercial clinical trial funders and sponsors to sign up to the WHO Joint Statement and fully implement its provisions in order to safeguard the interests of patients, strengthen public health, and reduce costly research waste.

 

 

Share on Facebook
Share on Twitter
Please reload

Subscribe
Subscribe
Recent Posts
Please reload

This site was designed with the
.com
website builder. Create your website today.
Start Now